The biotech sector is filled with mispriced securities after an era of easy money in 2020, according to Janus Henderson’s Agustin Mohedas.

The biotech sector is filled with mispriced securities after an era of easy money in 2020, according to Janus Henderson’s Agustin Mohedas.
Neil Robson, head of global equities at Columbia Threadneedle Investments, explains the rationale behind long/short investing.
Olivier Blin, investment manager at Unigestion, answers three questions about risk premia strategies.
RWC Partners has launched a UCITS version of its Asia Absolute Alpha Fund.
Volatility in global markets has nudged private bank clients toward absolute return type funds, said Edmund Yun, executive director, head of investment for Asia at BMO Private Bank.
Less than half of the hedge funds offered in Hong Kong and Singapore have delivered more than 10% over the past three years.
Part of the Mark Allen Group.